28 January, 2025
Apellis’ SYFOVRE® (pegcetacoplan) TGA Approved
Apellis Pharmaceuticals, Inc. announced today that Australia’s Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the treatment of adult patients with geographic atrophy (GA). It is the first and only approved treatment for GA in Australia.
Retina Australia welcomed this milestone decision offering hope to the over 75,000 Australians living with geographic atrophy (GA), a severe form of age-related macular degeneration (AMD). This treatment provides the first real opportunity to slow vision loss, helping to preserve both quality of life and independence for those affected.
For more information, please refer the Apellis press release here.
Retina Australia was involved in the launch of the report Geographic Atrophy, We Can’t Wait and See: The Case for Action at Parliament House, Canberra, in September 2024.
Commissioned by Apellis Australia, the report aimed to assess the social impact of preserving vision in people living with GA. The report highlighted the urgent need for action and the significant social value of preserving vision for individuals affected by GA, with $2.21 of social value created for every $1 invested.
Retina Australia was a member of the Advisory Committee for the development of the report, along with other leading organisations in the eye heath and vision care sector – Macular Disease Foundation Australia (MDFA), Optometry Australia, Sight For All, Vision Australia and Vision 2020 Australia. The study was conducted by HTANALYSTS and report prepared by Crash Bang Wallop.
You can read a summary and access the a full copy of the report here.
https://retinaaustralia.com.au/first-treatment-for-geographic-atrophy-approved-in-australia/
Other Blogs
World Research Summary by Dr Catherine Civil
Hot Off The Press Check out below to see what new inherited retinal disease (IRD) therapies are in the pipeline! Base...
Podcast: Mental Health and Rare Eye Diseases
Perspectives Podcast by Retina International Guest speaker: Matt Bolz-Johnson, a mental health lead at EURORDIS-Rare Diseases Europe Retina International's Perspectives Podcasts...
New Research: Navigating a hidden disability – Lived experiences and challenges of adults with early stage inherited retinal diseases
Inherited retinal diseases (IRDs) are genetic conditions that typically...